Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

DOI Full Paper Access

128

Citations

24

References

2024

Year

Alexa B. Kimball, Gregor B. E. Jemec, Christopher J. Sayed, Joslyn S. Kirby, Errol P. Prens, John R Ingram, Amit Garg, Alice B. Gottlieb, Jacek C. Szepietowski, Falk G. Bechara,

Moderate-to-severe Hidradenitis SuppurativaBe Heard IiBe HeardClinical DermatologyDermatologyMedicine

References

	Year	Citations

Page 1